What type of study is this?

September 5, 2025Open Access

Figure S2 from Inhibition of MCL-1 and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers

View Full Paper

Ask AI

Bookmark

Inhibiting both MCL-1 and MEK may reverse resistance in triple-negative and inflammatory breast cancers, enhancing treatment efficacy.
The analysis identified significant siRNAs with a 5% false discovery rate using multiple normalization methods, indicating robust findings.
Normalization methods included Z-score, b-score, and regional scaling, underscoring the importance of technique in RNA analysis.
These findings highlight the potential for combinational therapies in addressing drug resistance in aggressive breast cancer subtypes.

Implication

Analysis compares siRNAs in untreated vs treated triple-negative and inflammatory breast cancers, suggesting effective strategies against inhibitors.

Abstract

Fig. S2 Venn diagram of the number of significant siRNAs identified with a 5% false discovery rate using different normalization methods (Z-score, b-score, and regional scaling) for comparison between untreated and treated samples.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mughees et al. (2025) studied this question.

synapsesocial.com/papers/68bb4e016d6d5674bcd02af4 https://doi.org/10.1158/1535-7163.30029546

View Full Paper

Ask AI

Bookmark

Implication

Analysis compares siRNAs in untreated vs treated triple-negative and inflammatory breast cancers, suggesting effective strategies against inhibitors.

Figure S2 from Inhibition of MCL-1 and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers

Key Points

Implication

Abstract

Discussion

Cite This Study

Figure S2 from Inhibition of MCL-1 and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading